Skip to main content
SAMJIN PHARMACEUTICAL CO.,LTD logo

SAMJIN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 005500 ISIN · KR7005500004 KO Manufacturing
Open in API
Filings indexed 253 across all filing types
Latest filing 2023-02-06 Earnings Release
Country KR South Korea
Listing KO 005500

About SAMJIN PHARMACEUTICAL CO.,LTD

https://www.samjinpharm.co.kr/

Samjin Pharmaceutical Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and sale of medicines. The company's portfolio includes a wide range of over-the-counter (OTC) and prescription drugs, offered in various formulations such as oral, drop, and injectable forms. Notable products include the analgesic Gevorin, the antiplatelet agent Plavix, and the hypercholesterolemia treatment Newstatin-R. A central part of its strategy is a strong commitment to R&D, focusing on creating innovative new drugs to address diseases with high unmet medical needs. The company actively develops novel therapeutics for severe conditions, including cardiovascular, respiratory, and gastrointestinal diseases, with the goal of becoming a global pharmaceutical innovator.

Recent filings

Filing Released Lang Actions
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 100% confidence The document is a regulatory filing from Samjin Pharmaceutical regarding a significant change in sales or profit structure (30% or more). It provides preliminary financial data (revenue, operating profit, net income) for the current and previous fiscal years. This type of disclosure is a standard regulatory requirement in the Korean market (DART system) to inform investors of material financial changes before the final audit report is published. Since it is an initial announcement of financial results rather than a full annual report or a simple report publication notice, it falls under the 'Earnings Release' category. FY 2022
2023-02-06 Korean
투자판단관련주요경영사항
Regulatory Filings Classification · 100% confidence The document is a formal regulatory disclosure from Samjin Pharmaceutical regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It details a strategic partnership agreement with AriBio for the clinical trial, production, and exclusive sales rights of a drug (AR1001). Since this is a specific regulatory announcement of a material business event that does not fit into financial reporting, dividend, or governance categories, it is classified as a general regulatory filing.
2023-02-03 Korean
주요사항보고서(자기주식취득신탁계약체결결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) from Samjin Pharmaceutical Co., Ltd. regarding the decision to enter into a trust agreement for the acquisition of treasury shares (자기주식취득 신탁계약 체결 결정). This is a regulatory filing detailing a corporate action involving the company's own shares, which falls under the category of 'Transaction in Own Shares' (POS).
2022-12-02 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing specifically details personal share transactions (insider trades) by company directors or executives. According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2022-12-01 Korean
분기보고서 (2022.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Samjin Pharmaceutical Co., Ltd. for the period ending September 30, 2022. It contains detailed financial statements, management discussion and analysis, and operational data, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2022
2022-11-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service and Korea Exchange. This is a standard regulatory filing in South Korea used to disclose insider trading or changes in share ownership by company executives. According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2022-10-28 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.